Intellia Therapeutics Inc. Common Stock (NTLA)

FairStock Score: 54/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor in the Buffett/Graham tradition, I start with what is proven. Intellia is a clinical-stage genome-editing company, so its CRISPR/Cas9 platform and in vivo/ex vivo candidates are promising, but there is no commercial earnings record to anchor value. In fiscal Q2 2026 (quarter ended 2026-06-30), revenue was $7.7M, down from $14.2M in fiscal Q2 2025 (quarter ended 2025-06-30), and net loss was $106.6M, or -$0.80 diluted EPS. Fiscal 2025 revenue was $67.7M, up from FY2024 $57.9M and FY2023 $36.3M, but losses were -$412.7M, -$519.0M, and -$481.2M respectively. That is not a business with durable earning power; it is a research engine funded by capital. The Lynch category is none - Loss in each of the last 4 years. Financial health is mixed: D/E 0.10 and Altman Z-Score 3.38 suggest low leverage, but trailing FCF is -$348.7M and FCF yield -20.9% (FairStock calculations). ROE -55.44% and ROCE -30.14% show capital is being consumed. At the 2026-10-13 close of $11.91, P/E is -3.57 and P/B 2.29 (FairStock calculations). With no profits, Graham-style intrinsic value is not visible; P/B is not cheap for a cash-burning clinical biotech. Any competitive moat rests on intellectual property and clinical execution, not on current financials. The stock may hold pipeline option value, but I cannot call the current business strong or the price supported by present numbers.

In plain English: Intellia Therapeutics is a clinical-stage healthcare company that uses gene-editing technology to try to develop new treatments, but it has no profits and is not yet a commercial business. Its latest reported quarter showed a loss and lower revenue than a year earlier, with heavy cash spending. At the 2026-10-13 price of $11.91, the shares do not look cheap based on the current numbers; the value depends on future medical results, not today's earnings.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer